These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39006503)

  • 1. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.
    Dietz J; Graf C; Berg CP; Port K; Deterding K; Buggisch P; Peiffer KH; Vermehren J; Dultz G; Geier A; Reiter FP; Bruns T; Schattenberg JM; Durmashkina E; Gustot T; Moreno C; Trauth J; Discher T; Fischer J; Berg T; Kremer AE; Müllhaupt B; Zeuzem S; Sarrazin C;
    JHEP Rep; 2024 Jul; 6(7):101072. PubMed ID: 39006503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
    Dietz J; Müllhaupt B; Buggisch P; Graf C; Peiffer KH; Matschenz K; Schattenberg JM; Antoni C; Mauss S; Niederau C; Discher T; Trauth J; Dultz G; Schulze Zur Wiesch J; Piecha F; Klinker H; Müller T; Berg T; Neumann-Haefelin C; Berg CP; Zeuzem S; Sarrazin C; ; ; ;
    J Hepatol; 2023 Jan; 78(1):57-66. PubMed ID: 36031158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents.
    Liu Z; Mao X; Yu K; Suo C; Jin L; Zhang T; Chen X
    J Viral Hepat; 2020 Jun; 27(6):585-592. PubMed ID: 32049405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.
    Dietz J; Kalinina OV; Vermehren J; Peiffer KH; Matschenz K; Buggisch P; Niederau C; Schattenberg JM; Müllhaupt B; Yerly S; Ringelhan M; Schmid RM; Antoni C; Müller T; Schulze Zur Wiesch J; Piecha F; Moradpour D; Deterding K; Wedemeyer H; Moreno C; Berg T; Berg CP; Zeuzem S; Welsch C; Sarrazin C;
    J Viral Hepat; 2020 Oct; 27(10):974-986. PubMed ID: 32396998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.
    Howe AYM; Rodrigo C; Cunningham EB; Douglas MW; Dietz J; Grebely J; Popping S; Sfalcin JA; Parczewski M; Sarrazin C; de Salazar A; Fuentes A; Sayan M; Quer J; Kjellin M; Kileng H; Mor O; Lennerstrand J; Fourati S; Di Maio VC; Chulanov V; Pawlotsky JM; Harrigan PR; Ceccherini-Silberstein F; Garcia F;
    JHEP Rep; 2022 May; 4(5):100462. PubMed ID: 35434589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
    Di Maio VC; Barbaliscia S; Teti E; Fiorentino G; Milana M; Paolucci S; Pollicino T; Morsica G; Starace M; Bruzzone B; Gennari W; Micheli V; Yu La Rosa K; Foroghi L; Calvaruso V; Lenci I; Polilli E; Babudieri S; Aghemo A; Raimondo G; Sarmati L; Coppola N; Pasquazzi C; Baldanti F; Parruti G; Perno CF; Angelico M; Craxì A; Andreoni M; Ceccherini-Silberstein F;
    Liver Int; 2021 Aug; 41(8):1802-1814. PubMed ID: 33497016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
    Dietz J; Di Maio VC; de Salazar A; Merino D; Vermehren J; Paolucci S; Kremer AE; Lara M; Pardo MR; Zoller H; Degasperi E; Peiffer KH; Sighinolfi L; Téllez F; Graf C; Ghisetti V; Schreiber J; Fernández-Fuertes E; Boglione L; Muñoz-Medina L; Stauber R; Gennari W; Figueruela B; Santos J; Lampertico P; Zeuzem S; Ceccherini-Silberstein F; García F; Sarrazin C; ; ;
    J Hepatol; 2021 Apr; 74(4):801-810. PubMed ID: 33220331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
    Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Dekhtyar T; Irvin M; Xie W; Fu B; Burroughs M; Redman R; Kumada H; Chayama K; Collins C; Pilot-Matias T
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents.
    Minosse C; Selleri M; Giombini E; Bartolini B; Capobianchi MR; Cerilli S; Loiacono L; Taibi C; D'Offizi G; McPhee F; Garbuglia A
    Infect Drug Resist; 2018; 11():2117-2127. PubMed ID: 30464554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
    Hezode C; Reau N; Svarovskaia ES; Doehle BP; Shanmugam R; Dvory-Sobol H; Hedskog C; McNally J; Osinusi A; Brainard DM; Miller MD; Mo H; Roberts SK; O'Leary JG; Shafran SD; Zeuzem S
    J Hepatol; 2018 May; 68(5):895-903. PubMed ID: 29221887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C.
    Itakura J; Kurosaki M; Kakizaki S; Amano K; Nakayama N; Inoue J; Endo T; Marusawa H; Hasebe C; Joko K; Wada S; Akahane T; Koushima Y; Ogawa C; Kanto T; Mizokami M; Izumi N
    JHEP Rep; 2020 Oct; 2(5):100138. PubMed ID: 32817930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline resistance-associated substitutions may impact DAA response among treatment failure chronic hepatitis C patients with pegylated interferon and ribavirin in real life.
    Ren S; Wei F; Jin Y; Lu J; He Z; Ma L; Zheng Y; Wang J; Chen X
    Antivir Ther; 2020; 25(5):245-255. PubMed ID: 32936785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study.
    Ji F; Tran S; Ogawa E; Huang CF; Suzuki T; Wong YJ; Toyoda H; Jun DW; Li L; Uojima H; Nozaki A; Chuma M; Tseng CH; Hsu YC; Ishigami M; Honda T; Atsukawa M; Haga H; Enomoto M; Trinh H; Preda CM; Vutien P; Landis C; Lee DH; Watanabe T; Takahashi H; Abe H; Asai A; Eguchi Y; Li J; Wang X; Li J; Liu J; Liang J; Lam CP; Huang R; Ye Q; Pan H; Zhang J; Cai D; Wang Q; Huang DQ; Wong G; Wong VW; Li J; Do S; Furusyo N; Nakamuta M; Nomura H; Kajiwara E; Yoon EL; Ahn SB; Azuma K; Dohmen K; An J; Song DS; Cho HC; Kawano A; Koyanagi T; Ooho A; Satoh T; Takahashi K; Yeh ML; Tsai PC; Yasuda S; Zhao Y; Liu Y; Okubo T; Itokawa N; Jun MJ; Ishikawa T; Takaguchi K; Senoh T; Zhang M; Zhao C; Alecu RI; Xuan Tay W; Devan P; Liu JK; Kozuka R; Vargas-Accarino E; Do AT; Maeda M; Chuang WL; Huang JF; Dai CY; Cheung R; Buti M; Niu J; Xie W; Ren H; Lim SG; Wu C; Yuen MF; Shang J; Zhu Q; Ueno Y; Tanaka Y; Hayashi J; Yu ML; Nguyen MH
    J Clin Transl Hepatol; 2024 Jul; 12(7):646-658. PubMed ID: 38993510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
    Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
    J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
    Smith DA; Bradshaw D; Mbisa JL; Manso CF; Bibby DF; Singer JB; Thomson EC; da Silva Filipe A; Aranday-Cortes E; Ansari MA; Brown A; Hudson E; Benselin J; Healy B; Troke P; McLauchlan J; Barnes E; Irving WL
    J Viral Hepat; 2021 Sep; 28(9):1256-1264. PubMed ID: 34003556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.
    Gozlan Y; Ben-Ari Z; Moscona R; Shirazi R; Rakovsky A; Kabat A; Veizman E; Berdichevski T; Weiss P; Cohen-Ezra O; Lurie Y; Gafanovich I; Braun M; Cohen-Naftaly M; Shlomai A; Shibolet O; Zigmond E; Zuckerman E; Carmiel-Haggai M; Nimer A; Hazzan R; Maor Y; Kitay-Cohen Y; Shemer-Avni Y; Kra-Oz Z; Schreiber L; Peleg O; Sierra S; Harrigan PR; Mendelson E; Mor O
    Antivir Ther; 2017; 22(5):431-441. PubMed ID: 28067632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
    Fahnøe U; Pedersen MS; Sølund C; Ernst A; Krarup HB; Røge BT; Christensen PB; Laursen AL; Gerstoft J; Thielsen P; Madsen LG; Pedersen AG; Schønning K; Weis N; Bukh J
    J Viral Hepat; 2021 Feb; 28(2):302-316. PubMed ID: 33131178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing.
    Nguyen T; Akhavan S; Caby F; Bonyhay L; Larrouy L; Gervais A; Lebray P; Poynard T; Calmus Y; Simon A; Valantin MA; Calvez V; Marcelin AG; Todesco E
    Int J Antimicrob Agents; 2019 Jan; 53(1):80-83. PubMed ID: 30236959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.